Logo
AICAR 50mg

AICAR 50mg

AICAR

Research peptide / small-molecule reagent
  • No UK MHRA marketing authorisation is listed for this commercial AICAR 50mg research product as a medicinal product.
  • The product is not described as a CE Marked medical device; it is offered as a research chemical rather than as a regulated medical device or medicine.
  • AICAR (as a compound) appears on the World Anti Doping Agency (WADA) list of prohibited substances for sports due to its potential performance Enhancing effects, but this is a regulatory status for sporting competition rather than a marketing authorisation for this product.
Adenosine monophosphate (AMP) analogue; AMP-activated protein kinase (AMPK) activator; lyophilised powder for laboratory research

Description

AICAR 50mg is a research-grade preparation of AICAR (5-aminoimidazole-4-carboxamide ribonucleoside), a synthetic analogue of adenosine monophosphate (AMP). AICAR is an AMP mimetic that is phosphorylated intracellularly to the monophosphate form (often referred to as ZMP), which activates AMP-activated protein kinase (AMPK) and modulates cellular energy homeostasis. Commercial peptide and research suppliers describe AICAR 50mg as a lyophilised powder supplied for in vitro and laboratory research use only, not for human or veterinary administration. In scientific and clinical research, AICAR (and related formulations such as acadesine) has been investigated as a cardioprotective agent in settings of myocardial ischaemia, for effects on glucose and lipid metabolism, insulin sensitivity, inflammation, and various experimental cancer and metabolic models. The descriptive text widely used by research suppliers states that AICAR is an analogue of adenosine monophosphate, has been used clinically to protect against cardiac ischaemia following heart attack, has antioxidant properties, and is under investigation for potential roles in diabetes, autoimmune disease, and other inflammatory conditions; however, these research claims do not constitute approved therapeutic indications for this commercial 50 mg research product.

Bnefits

  • Functions as an analogue of adenosine monophosphate (AMP), allowing experimental activation of AMP-activated protein kinase (AMPK) in intact cells.
  • Widely used in laboratory research to study cellular energy homeostasis, insulin signalling, glucose uptake, and lipid metabolism.
  • Has been investigated experimentally for cardioprotective effects in models of myocardial ischaemia and doxorubicin-induced heart failure.
  • Used in pre-clinical research on diabetes, obesity, insulin resistance, and metabolic syndrome via modulation of AMPK and related pathways.
  • Explored in experimental models for anti-inflammatory effects and modulation of oxidative stress.
  • Studied in cancer research as an AMPK activator affecting tumour cell proliferation, metabolism, and survival.
  • Supplied in a defined 50 mg quantity, typically as a lyophilised powder for reconstitution to controlled concentrations in research protocols.
  • Commercial research suppliers emphasise high-purity, laboratory-only use, providing a consistent reagent for reproducible experiments.

Indications

  • No authorised therapeutic indications – this product is marketed exclusively as a research chemical/reagent and is not approved as a medicine or medical device.
  • In scientific and investigational contexts (not specific to this commercial product), AICAR/acadesine has been studied as a cardioprotective agent in myocardial ischaemia and heart failure models.
  • AICAR is used in pre-clinical research to investigate mechanisms relevant to diabetes, insulin resistance, dyslipidaemia, inflammation, and certain cancers through AMPK activation.
  • Any clinical or prophylactic uses described in the literature relate to investigational drug studies and not to approved indications for this 50 mg research product.

Composition

  • Active substance: AICAR (5-aminoimidazole-4-carboxamide ribonucleoside).
  • Strength: 50 mg of AICAR per unit, as stated by multiple research suppliers for AICAR 50mg products.
  • Empirical formula: C9H15N4O8P.
  • Molecular weight: approximately 338.21 g/mol.
  • Common synonyms: AICA ribonucleotide, 5-aminoimidazole-4-carboxamide ribonucleoside, Z-nucleotide, ZMP precursor.
  • CAS number: 3031-94-5.
  • Excipients, residual solvents, and stabilisers for the Derma Filler Ltd product: Not publicly listed.
  • Purity specification, analytical profile, and impurity limits for this product: Not publicly listed.

Formulation

  • Small-molecule nucleoside analogue supplied as a research reagent.
  • Commercial AICAR 50mg products are described by multiple suppliers as arriving in lyophilised (freeze-dried) powder form for maximum stability; the Derma Filler Ltd specific physical presentation is not separately described.
  • Intended for reconstitution with an appropriate solvent (e.g. bacteriostatic water or other laboratory diluent) for in vitro and experimental use, according to local laboratory protocols.
  • No authorised or standardised medicinal dosage form (such as tablet or approved injectable medicinal product) is specified for this commercial 50 mg research product.

Packaging

  • Typically supplied in a sealed vial or container containing 50 mg of lyophilised AICAR powder; Derma Filler Ltd’s site does not provide detailed packaging specifications.
  • No publicly available information specifies the exact vial material, stopper type, secondary carton design, or label artwork for the Derma Filler Ltd AICAR 50mg product.
  • Batch number, expiry date, and storage labelling details are not reproduced in publicly accessible images or text and must be taken from the physical pack and accompanying documentation.

Usage

  • Derma Filler Ltd does not publish detailed preparation or usage instructions for AICAR 50mg; the product is sold as a research chemical.
  • Other research suppliers state that AICAR 50mg is supplied as a lyophilised powder intended to be reconstituted with a suitable solvent (often bacteriostatic water) immediately prior to experimental use, following laboratory protocols.
  • Research peptide vendors explicitly state that AICAR products are for laboratory and research use only and are not intended for human or veterinary consumption, injection, or other clinical use.
  • No dosing regimen, route of administration, or treatment protocol is provided for clinical use, and users are instructed not to enquire about human dosing or therapeutic administration.
  • Handling should follow general laboratory safety practices for research chemicals, including appropriate personal protective equipment and waste disposal measures in accordance with local regulations.

Contraindications

  • Not publicly listed for this research product.
  • Research suppliers uniformly specify that AICAR 50mg is not for human or veterinary use; therefore, standard clinical contraindication listings are not provided for this commercial preparation.

Adverse Effects

  • Not publicly listed for this research product.
  • Any adverse-effect information on AICAR or its prodrug acadesine originates from experimental and clinical research literature and is not included as product-specific safety information for this 50 mg research reagent.

Storage Conditions

  • Derma Filler Ltd does not provide product-specific storage instructions for AICAR 50mg on publicly accessible pages.
  • Other AICAR peptide suppliers advise storing the lyophilised powder in a dry, cool, dark place away from UV light, with best preservation at refrigerated temperature (around 4 °C).
  • Users are generally instructed to follow the storage information printed on the product label and in any accompanying documentation for the specific batch supplied.
  • No shelf-life or expiry period is publicly specified for the Derma Filler Ltd AICAR 50mg product.

Duration

Not publicly listed (no authorised therapeutic regimen or treatment duration exists for this commercial research product).

Onset

Not publicly listed (no product-specific clinical onset-of-action information is provided; published effects of AICAR relate to experimental and investigational settings).

Browse more Research peptide / small-molecule reagent

Top Treatments

Top Cities in the UK